Perrigo Company PLC Share Price TEL AVIV STOCK EXCHANGE
Equities
IE00BGH1M568
Pharmaceuticals
Sales 2024 * | 4.66B 1,726B 371B | Sales 2025 * | 4.86B 1,802B 388B | Capitalization | 4.44B 1,646B 354B |
---|---|---|---|---|---|
Net income 2024 * | -51M -18.9B -4.07B | Net income 2025 * | 105M 38.9B 8.37B | EV / Sales 2024 * | 1.64 x |
Net Debt 2024 * | 3.19B 1,183B 255B | Net Debt 2025 * | 3.06B 1,132B 244B | EV / Sales 2025 * | 1.54 x |
P/E ratio 2024 * |
-44.9
x | P/E ratio 2025 * |
121
x | Employees | - |
Yield 2024 * |
3.35% | Yield 2025 * |
3.57% | Free-Float | 99.69% |
Latest transcript on Perrigo Company PLC
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 29/06/23 | |
Eduardo Bezerra
DFI | Director of Finance/CFO | 49 | 15/05/22 |
Alison Ives
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Orlando Ashford
CHM | Chairman | 55 | 14/12/20 |
Jeffrey Kindler
BRD | Director/Board Member | 68 | 05/02/17 |
Bradley Alford
BRD | Director/Board Member | 67 | 05/02/17 |
1st Jan change | Capi. | |
---|---|---|
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |